Evidence map›Paper›PMID 40392465›Full record

Trial reportInternational journal of hematology2025

A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.

Hiroki Yamaguchi, Masaki Iino, Shugo Kowata, Ryusuke Yamamoto, Jun Yamanouchi, Yutaka Imamura, Keita Kirito, Kenji Yokoyama, Tomoki Ito, Tatsunori Ishikawa and 5 more

Erratum issued 2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05369208 phase3completednot on this map

An Open-label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic Immune Thrombocytopenia

TypeinterventionalSponsorSobi, Inc.Ran2022 to 2025Enrolled19ConditionsImmune ThrombocytopeniaArmsAvatrombopag Oral Tablet
NCT07133659 phase4recruitingnot on this map

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

TypeinterventionalSponsorAl-Mustansiriyah UniversityRan2025 to 2027Enrolled25ConditionsITP - Immune ThrombocytopeniaArmsAvatrombopag 20 mg Oral Tablet
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Hiroki YamaguchiDepartment of Hematology, Nippon Medical School Hospital, Tokyo, Japan. y-hiroki@fd6.so-net.ne.jp.ORCID http://orcid.org/0000-0002-0571-7495
Masaki IinoDepartment of Hematology and Hematopoietic Stem Cell Transplantation, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.ORCID http://orcid.org/0000-0002-3471-0890
Shugo KowataDivision of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Ryusuke YamamotoDepartment of Hematology, Kobe City Medical Center General Hospital, Hyogo, Japan.
Jun YamanouchiDivision of Blood Transfusion and Cell Therapy, Ehime University Hospital, Ehime, Japan.
Yutaka ImamuraDivision of Hematology, St. Mary's Hospital, Fukuoka, Japan.
Keita KiritoUniversity of Yamanashi, Yamanashi, Japan.
Kenji YokoyamaTokai University Hachioji Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2452-7248
Tomoki ItoKansai Medical University, Osaka, Japan.ORCID http://orcid.org/0000-0001-5419-9156
Tatsunori IshikawaChugoku Central Hospital, Hiroshima, Japan.
Motoaki ShiratsuchiAso Iizuka Hospital, Fukuoka, Japan.ORCID http://orcid.org/0000-0002-0403-0122
Yoshiaki TomiyamaDepartment of Blood Transfusion, Osaka University Hospital, Osaka, Japan.ORCID http://orcid.org/0000-0001-7645-0989
Harumi KamiyaSobi, K.K., Tokyo, Japan.
Jessica ZhangSobi, Inc, Morrisville, NC, USA.
Brian D JamiesonSobi, Inc, Morrisville, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Avatrombopag is an oral thrombopoietin receptor agonist approved widely for the treatment of adults with chronic immune thrombocytopenia (ITP). However, data in Japanese patients are limited. This confirmatory phase 3, open-label study investigated avatrombopag (initial dose 20 mg/day) in Japanese adults (aged ≥ 18 years) with chronic ITP (≥ 12 months), insufficient response to prior treatment and an average of 2 platelet counts (PCs) < 30 × 10

Indexed as

Purpura, Thrombocytopenic, IdiopathicThiazolesThiophenesAdultAgedBlood PlateletsChronic DiseaseEast Asian PeopleFemaleHumansJapanMaleMiddle AgedPlatelet CountReceptors, ThrombopoietinTreatment OutcomeavatrombopagReceptors, ThrombopoietinThiazolesThiophenesClinical trialITPJapanThrombopoietin receptor agonist

Identifiers

PMID40392465
PMCPMC12476303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.